Globus Medical Reports Third Quarter 2025 Results

Core Insights - Globus Medical, Inc. reported a strong financial performance for Q3 2025, with revenue increasing by 23% year-over-year, driven by a 10% growth in the US Spine business and strong demand across products and geographies [2][3] - The company achieved record non-GAAP free cash flow of $213.9 million, up 24% quarter-over-quarter, and non-GAAP diluted earnings per share of $1.18, a 43% increase compared to the same quarter last year [2][4] - The company raised its full-year 2025 revenue guidance to a range of $2.86 to $2.90 billion and non-GAAP fully diluted earnings per share to a range of $3.75 to $3.85, indicating confidence in future growth [5] Financial Performance - Worldwide net sales for Q3 2025 were $769.0 million, a 22.9% increase from Q3 2024, with US net sales rising by 24.6% and international sales increasing by 16.5% [2][7] - GAAP net income for Q3 2025 was $119.0 million, reflecting a 129.5% increase year-over-year, primarily due to higher sales, including $99.3 million from the Nevro acquisition [3][7] - Non-GAAP diluted EPS for Q3 2025 was $1.18, up 42.6% from $0.83 in Q3 2024 [3][40] Cash Flow and Capital Management - Net cash provided by operating activities was $249.7 million for Q3 2025, contributing to a non-GAAP free cash flow of $213.9 million [4][43] - The company executed share repurchases totaling $40 million in the quarter, bringing the total for the first nine months of 2025 to $255.5 million, demonstrating a commitment to shareholder value [2][4] Strategic Acquisitions - The integration of the recently acquired Nevro business has exceeded expectations, contributing significantly to revenue growth and underscoring the effectiveness of the company's integration strategy [2][3] - The Nevro acquisition is expected to be accretive to earnings in 2025, further enhancing the company's growth prospects [5] Market Position and Outlook - The company remains focused on achieving consistent organic growth through innovation and disciplined execution, aiming to finish 2025 strong [2][5] - The strong performance in Q3 highlights the company's ability to balance growth with operational efficiency and synergy execution [2][3]